A Need for Further Education on Buprenorphine in Pain Medicine
With the ongoing opioid epidemic in the United States there has been a strong transition towards utilizing multi-modal analgesia, interventional procedures, and non-opioid medications when managing acute and chronic pain. There has also been an increased interest in utilizing buprenorphine. Buprenorphine is a novel long-acting analgesic with partial mu-opioid agonist activity that can be utilized for analgesia as well as opioid use disorder. Buprenorphine also has a unique set of side effects as well pharmacodynamic and pharmacokinetic properties that require special attention, especially if these patients require future surgical interventions. Given the increased interest in this medication we believe that there needs to be increased education and awareness regarding this medication amongst physicians, specifically pain management physicians and trainees.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
---|---|
Enthalten in: |
Health psychology research - 11(2023) vom: 15., Seite 74958 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Hasoon, Jamal [VerfasserIn] |
---|
Links: |
---|
Themen: |
Acute pain |
---|
Anmerkungen: |
Date Revised 28.09.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.52965/001c.74958 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM359064817 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM359064817 | ||
003 | DE-627 | ||
005 | 20231226080057.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.52965/001c.74958 |2 doi | |
028 | 5 | 2 | |a pubmed24n1196.xml |
035 | |a (DE-627)NLM359064817 | ||
035 | |a (NLM)37405316 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Hasoon, Jamal |e verfasserin |4 aut | |
245 | 1 | 2 | |a A Need for Further Education on Buprenorphine in Pain Medicine |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 28.09.2023 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a With the ongoing opioid epidemic in the United States there has been a strong transition towards utilizing multi-modal analgesia, interventional procedures, and non-opioid medications when managing acute and chronic pain. There has also been an increased interest in utilizing buprenorphine. Buprenorphine is a novel long-acting analgesic with partial mu-opioid agonist activity that can be utilized for analgesia as well as opioid use disorder. Buprenorphine also has a unique set of side effects as well pharmacodynamic and pharmacokinetic properties that require special attention, especially if these patients require future surgical interventions. Given the increased interest in this medication we believe that there needs to be increased education and awareness regarding this medication amongst physicians, specifically pain management physicians and trainees | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a acute pain | |
650 | 4 | |a buprenorphine | |
650 | 4 | |a chronic pain | |
650 | 4 | |a education | |
650 | 4 | |a opioids | |
650 | 4 | |a pain medicine | |
700 | 1 | |a Nguyen, Anvinh |e verfasserin |4 aut | |
700 | 1 | |a Urits, Ivan |e verfasserin |4 aut | |
700 | 1 | |a Robinson, Christopher |e verfasserin |4 aut | |
700 | 1 | |a Viswanath, Omar |e verfasserin |4 aut | |
700 | 1 | |a Kaye, Alan D |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Health psychology research |d 2013 |g 11(2023) vom: 15., Seite 74958 |w (DE-627)NLM243870574 |x 2420-8124 |7 nnns |
773 | 1 | 8 | |g volume:11 |g year:2023 |g day:15 |g pages:74958 |
856 | 4 | 0 | |u http://dx.doi.org/10.52965/001c.74958 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 11 |j 2023 |b 15 |h 74958 |